Literature DB >> 20574164

Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix.

Yoo-Young Lee1, In-Gu Do, Young Ae Park, Jung-Joo Choi, Sang Yong Song, Chul Jung Kim, Min Kyu Kim, Tae Jong Song, Hwang Shin Park, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Jeong-Won Lee, Duk-Soo Bae.   

Abstract

Dynamin 2 is known as a protein involved in cell migration and endocytosis. We aimed to investigate the association between dynamin 2 expressions and tumor progression in early cervical carcinoma (IB1-IIA). Dynamin 2 expression was evaluated at protein level in thirty seven paraffin-embedded, formalin-fixed tissues including four normal cervix tissues and compared with pathologic risk factors for recurrence after surgery in thirty three patients with squamous cell carcinoma of the cervix. The expression of dynamin 2 was not different according to clinical stage and lympho-vascular space invasion. However, there were inverse correlations between dynamin 2 expression and the depth of invasion in cervix (p = 0.003) and lymph node (LN) metastasis (p = 0.001). To evaluate the mechanism of dynamin 2 in tumor invasion and metastasis, we performed an in vitro experiment with dynamin 2 siRNA using several cervical carcinoma cell lines such as HeLa, MS751 and SiHa cells. We found the inhibition of dynamin 2 using specific siRNA enhanced the expression of matrix metalloproteinase-2. These results suggested that dynamin 2 might be involved in preventing tumor invasion and LN metastasis, possibly in relation with extracellular matrix degradation, and may be a prognostic marker for these risk factors in early squamous cell carcinoma of the cervix.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574164     DOI: 10.4161/cbt.10.4.12275

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

1.  Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma.

Authors:  Chaojie Gong; Jubo Zhang; Lan Zhang; Yingcong Wang; Hui Ma; Weizhong Wu; Jiefeng Cui; Yanhong Wang; Zhenggang Ren
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 2.  Dynamins and BAR Proteins-Safeguards against Cancer.

Authors:  Anna C Sundborger; Jenny E Hinshaw
Journal:  Crit Rev Oncog       Date:  2015

Review 3.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

4.  Expression of DNM3 is associated with good outcome in colorectal cancer.

Authors:  Shao-Ang Cheng; Xin Huang; Liang Jiang; Qi-Lian Liang; Xiao-Cui Hong; Hai-Xia Yang; Ke-Hui Hu; Xing-Bo Luo; Hui-Jie Zhang
Journal:  Open Med (Wars)       Date:  2022-01-24

5.  TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma.

Authors:  Gabija JuknytĖ; Inga LaurinaitytĖ; Alvita VilkeviČiŪtĖ; Greta GedvilaitĖ; Brigita GlebauskienĖ; Loresa KriauČiŪnienĖ; Rasa LiutkeviČienĖ
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis.

Authors:  Yoshikuni Inokawa; Shuji Nomoto; Mitsuhiro Hishida; Masamichi Hayashi; Mitsuro Kanda; Yoko Nishikawa; Shin Takeda; Michitaka Fujiwara; Masahiko Koike; Hiroyuki Sugimoto; Tsutomu Fujii; Goro Nakayama; Suguru Yamada; Chie Tanaka; Daisuke Kobayashi; Yasuhiro Kodera
Journal:  Onco Targets Ther       Date:  2013-10-09       Impact factor: 4.147

7.  Construction of a recombinant eukaryotic expression vector containing DNM3 gene and its expression in colon cancer cells.

Authors:  Liang Jiang; Qi-Lian Liang; Wei-Ming Liang; Hui-Jie Zhang; Jie Huang; Gao-Le Yuan; Xiao-Xia Peng; Shao-Ang Cheng; Zhi-Gang Huang; Xiang-Ning Zhang
Journal:  Onco Targets Ther       Date:  2018-10-09       Impact factor: 4.147

Review 8.  A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.

Authors:  Delphine Trochet; Marc Bitoun
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.